Document Detail


Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
MedLine Citation:
PMID:  23318985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices.
METHODS: Data obtained from the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory physicians, were used to examine trends in office visits by children and adolescents (under age 18) during which ADHD was treated with Adderall, other psychostimulants, or atomoxetine. Segmented time series regressions were conducted to determine changes in use associated with three advisories issued between 2005 and 2007.
RESULTS: In 2004, before the first FDA advisory, Adderall accounted for 36% of ADHD pharmacotherapy treatment visits. Other stimulants accounted for 46%, and atomoxetine accounted for 19%. Overall pharmacotherapy treatment rates were stable over the study period, but by 2008 the treatment visits accounted for by Adderall (that is, market share) declined to 24%, and the market share for atomoxetine declined to 8%. The market share for substitute therapies-clonidine, guanfacine, and bupropion-was stable over this period, ranging from 5% to 7%. Despite the declines in the use of Adderall and atomoxetine over the study period, results from the regression models suggest that the advisories did not have a statistically significant effect on ADHD medication prescribing.
CONCLUSIONS: FDA advisories regarding potential cardiovascular and other risks of ADHD medications had little discernible incremental effect on the use of these medicines in this nationally representative ambulatory audit.
Authors:
Rachel Kornfield; Sydeaka Watson; Ashley S Higashi; Rena M Conti; Stacie B Dusetzina; Craig F Garfield; E Ray Dorsey; Haiden A Huskamp; G Caleb Alexander
Related Documents :
3227205 - The use of focus groups in health research.
20179015 - Health promoting health services: a review of the evidence.
24649735 - Powering the information engine.
12669625 - A psychosocial-approached health promotion program at a japanese worksite.
25081495 - Update on the possible nutritional importance of silicon.
15317315 - Hhs head looks to speed up it use in healthcare.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Psychiatric services (Washington, D.C.)     Volume:  64     ISSN:  1557-9700     ISO Abbreviation:  Psychiatr Serv     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-01     Completed Date:  2013-09-20     Revised Date:  2014-05-21    
Medline Journal Info:
Nlm Unique ID:  9502838     Medline TA:  Psychiatr Serv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  339-46     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adrenergic Uptake Inhibitors / therapeutic use*
Adrenergic alpha-2 Receptor Agonists / therapeutic use
Amphetamines / therapeutic use*
Attention Deficit Disorder with Hyperactivity / drug therapy*
Bupropion / therapeutic use
Central Nervous System Stimulants / therapeutic use*
Child
Clonidine / therapeutic use
Dopamine Uptake Inhibitors / therapeutic use
Drug Utilization
Guanfacine / therapeutic use
Humans
Physician's Practice Patterns / statistics & numerical data*
Propylamines / therapeutic use*
United States
United States Food and Drug Administration*
Grant Support
ID/Acronym/Agency:
HS0189960/HS/AHRQ HHS; K07 CA138906/CA/NCI NIH HHS; T32 MH019733/MH/NIMH NIH HHS; T32MH019733-17/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Adderall; 0/Adrenergic Uptake Inhibitors; 0/Adrenergic alpha-2 Receptor Agonists; 0/Amphetamines; 0/Central Nervous System Stimulants; 0/Dopamine Uptake Inhibitors; 0/Propylamines; 01ZG3TPX31/Bupropion; 30OMY4G3MK/Guanfacine; ASW034S0B8/atomoxetine; MN3L5RMN02/Clonidine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Balanced chromosomal translocations in men: relationships among semen parameters, chromatin integrit...
Next Document:  Active Surveillance for Prostate Cancer: Overview and Update.